Immunohistochemistry of prostate cancer patient samples revealed that of the 80 clinical cancers examined, 69 specimens (86.3%) were immunoreactive for MDK, with metastatic lesions showing higher expression than the corresponding primary tumors [50]. This evidence concerns the gene MDK and prostate carcinoma.